Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings (Tables)

v3.20.2
Long-Term Debt and Other Financings (Tables)
6 Months Ended
Jun. 30, 2020
Long-Term Debt and Other Financings  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of June 30, 2020, are as follows (in thousands):

2020 (excluding six months ended June 30, 2020)

$

3,750

2021

8,534

2022

21,200

Thereafter

Total payments

33,484

Less: interest, final payment fees, discount and issuance costs

(2,391)

Total payments, net of interest, final payment fees, discount and issuance costs

31,093

Less: current portion of long-term debt

(7,596)

Long-term debt

 

$

23,497

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss relates to the following debt instruments (in thousands):

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2020

    

2019

    

2020

    

2019

SVB loans

$

356

$

236

$

739

$

477

Novartis note

 

151

 

186

 

309

 

372

Other

 

1

 

1

 

2

 

3

Total interest expense

$

508

$

423

$

1,050

$

852